Physician
Oncology
Dr. Kendrith M. Rowland, MD
|
|
Give Review
Kendrith Rowland works in the field of Oncology. He studied medicine at University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago is ranked 49/85 in Research/PrimaryCare. Kendrith Rowland is also published. He has 48 publications published. The lastest publication: "A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321.
- Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
- Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
- The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast Cancer, N00C9.
- 14-3-3? as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and -negative breast Cancers.
- Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal Carcinoma.
- Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients wi...
- The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for Cancer: a phase III randomized, placebo-controlled, double-...
- Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole Brain radiation therapy?
- The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.
- Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treat...
- Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenoCarcinoma: Southwest Oncology Group-directed intergro...
- Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemci...
- Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung Cancer, N0423.
- Gabapentin for the management of hot flashes in prostate Cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB.
- Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian Cancer: final survival results of a SWOG (S0200) phase 3 randomiz...
- Optical coherence tomography: the intraoperative assessment of lymph nodes in breast Cancer.
- Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung Cancer: NCCTG and SWOG study N0426.
- Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1.
- Endpoints in phase II trials for advanced non-small cell lung Cancer.
- Intraoperative evaluation of Breast tumor margins with optical coherence tomography.
- Clinical feasibility of microscopically-guided Breast needle biopsy using a fiber-optic probe with computer-aided detection.
- Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung Cancer.
- Prognostic factors differ by tumor stage for small cell lung cancer: a pooled Analysis of North Central Cancer Treatment Group trials.
- Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced coloRectal carcinoma previously treated wi...
- A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).
- Phase II trial of sorafenib in patients with metastatic breast Cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Cl...
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group...
- A dose-escalation study of aerosolized sargramostim in the treatment of metastatic Melanoma: an NCCTG Study.
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
- Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal Cancer: phase II results from th...
- A placebo-controlled double blind trial of etanercept for the Cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
- Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic coloRectal cancer.
- Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.
- Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon Cancer.
- Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.
- Low-molecular-weight heparin in patients with advanced Cancer: a phase 3 clinical trial.
- Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent met...
- Phase III study of two different dosing schedules of erythropoietin in anemic patients with Cancer.
- Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastat...
- Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
- Phase II study of gemcitabine plus cisplatin in patients with metastatic breast Cancer: a North Central Cancer Treatment Group Trial.
- Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
- Randomized phase II study of two irinotecan schedules for patients with metastatic breast Cancer refractory to an anthracycline, a taxane, or both.
- A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate Carcinoma.
- Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with Malignant melanoma.
- A phase II trial of docetaxel and CPT-11 in patients with metastatic adenoCarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Schools
University Of Illinois College Of Medicine Chicago
University Ill Hospital
Rush Med College
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- American Republic
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care of Illinois PPO
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Health Alliance PPO
- HealthLink PPO
- Humana
- Medicare MCR
- Medico
- MultiPlan PPO
- PHCS Network PPO
- Pekin Insurance
- Thrivent Financial
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Rush University Medical Center -
University of Illinois College of Medicine at Chicago -
University of Illinois College of Medicine
Hospital
-
Carle Foundation Hospital
Drug Facts
| NPI NUMBER | 1407955206 | |
| NPPES Provider LastName | ROWLAND | |
| NPPES Provider FirstName | KENDRITH | |
| NPPES Provider ZIPCode | 618012500 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 2616.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 258.0 | |
| Percent Opioid Claims | 9.86 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1407955206 |
| Last Name Of The Provider | ROWLAND |
| First Name Of The Provider | KENDRITH |
| View All |
Similar Doctors
|
|
Dr. Pramern Sriratana, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wenqing Zhang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vamsi K. Vasireddy, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Safwat W. Wahba, MD |